Pulike Biological Engineering, Inc.

603566

CNE1000025N0

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-13 EDT			5-day change	1st Jan Change
14.73 ^CNY	-2.58%		-2.06%	-34.97%

04-25	Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Pulike Biological Engineering. Inc. Announces Cash Dividend for the Year 2016; Appoints Board of Directors

May 08, 2017 at 11:31 pm

Pulike Biological Engineering, Inc. announced that AGM was held on May 8, 2017, the shareholders approved the cash dividend of CNY 2 per ten shares for 2016.

The shareholders also approved the appointment of Qin Dechao, Ma Suiying as non-independent directors and Jin Ningyi, Wei Gang, Zou Xin as independent directors.

Latest news about Pulike Biological Engineering, Inc.

Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.	03-31	CI
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.	01-02	CI
Pulike Biological's Vaccine for Feline Respiratory Diseases Passes Chinese Emergency Evaluation	12-07	MT
Pulike Biological Engineering, Inc. announces an Equity Buyback for CNY 120 million worth of its shares.	11-13	CI
Pulike Biological Engineering, Inc. authorizes a Buyback Plan.	11-12	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-15	CI
Pulike Biological Engineering, Inc.(XSSC:603566) added to S&P Global BMI Index	23-09-18	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Pulike Biological Engineering, Inc. agreed to acquire Luoyang Lechong Health Technology Co., Ltd. from Shiji Mengbang Information Technology Co., Ltd. and Luoyang Jidi Biotechnology Center (Limited Partnership) for CNY 23.5 million.	23-06-30	CI
Pulike Biological Engineering Gets Certificate for Respiratory Drug for Chickens	23-05-08	MT
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Frontier IP investee develops vaccine candidate for Streptococcus suis	22-12-02	AN
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Pulike Biological Engineering Unit’s New Drug Wins Registration Certificate	22-10-19	MT
Pulike Biological Engineering, Inc. announced that it has received CNY 897.999976 million in funding from a group of investors	22-09-06	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
CAHIC ZENAQ Animal Pharmaceutical Co., Ltd announced that it expects to receive CNY 82.72 million in funding from China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc.	22-07-17	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Pulike Biological Engineering, Inc. announced that it expects to receive CNY 900 million in funding from a group of investors	21-11-14	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-29	CI

Chart Pulike Biological Engineering, Inc.

Duration

Period

Chart Pulike Biological Engineering, Inc.

More charts

Company Profile

Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Pulike Biological Engineering, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.73 CNY

Average target price

20.24 CNY

Spread / Average Target

+37.37%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
PULIKE BIOLOGICAL ENGINEERING, INC.	-34.97%	719M
ZOETIS INC.	-13.59%	78.17B
BLUESTAR ADISSEO COMPANY	+21.62%	3.62B
VIRBAC	-5.56%	3.09B
VIMIAN GROUP AB	+13.68%	1.68B
VETOQUINOL SA	-5.27%	1.3B
JINYU BIO-TECHNOLOGY CO., LTD.	-29.81%	1.18B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-31.11%	1.15B
WUHAN KEQIAN BIOLOGY CO.,LTD	-22.47%	1.02B
SWEDENCARE AB	-3.22%	926M

Veterinary Drugs